

14 December 2018

Salvarx Group plc

("SalvaRx" or the "Company")

Nominated Adviser Status

SalvaRx announces that the Directors have been advised by its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland"), of its proposed merger with SP Angel Corporate Finance LLP ("SP Angel"). Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7.00 a.m. on 1 February 2019.

As a result, it is the intention of the Directors to transition the Company's Nomad role from Northland to SP Angel. This process has already started and at present the Company anticipates a smooth and orderly transition of the Nomad role.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. In the event that the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

Enquiries:

SalvaRx Group plc

Ian Walters (Chief Executive)

Tel: +1 203-441-5451

Northland Capital Partners Limited

Tel: +44 (0) 20 3861 6625

Nominated Adviser and Broker

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Peterhouse Capital Limited

Tel: +44 (0) 20 7469 0932

Joint Broker

Lucy Williams / Duncan Vasey